ABCB1 and neoplasm: Moreover, in vitro and in vivo pharmacologic activities have shown that T-DXd showed potent anti-tumor activity against tumor cells that were resistant to T-DM1, which is likely due to a higher susceptibility of T-DM1 to p-glycoprotein mediated efflux, while T-DXd was not subject to this drug efflux mechanism.